Kitamura Kazuyoshi, Chiba Tatsuya, Mabuchi Fumihiko, Ishijima Kiyotaka, Omoto Shu, Kashiwagi Fumiko, Godo Takashi, Kogure Satoshi, Goto Teruhiko, Shibuya Takashi, Tanabe Jhoji, Tsukahara Shigeo, Tsuchiya Tadaharu, Tsumura Toyoaki, Tokunaga Takaharu, Hosaka Osamu, Saito Tetsunori, Kashiwagi Kenji
Department of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan.
Department of Ophthalmology, Irumagawa Hospital, Sayama, Saitama, Japan.
J Ophthalmol. 2018 Feb 21;2018:8456764. doi: 10.1155/2018/8456764. eCollection 2018.
To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy.
Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy.
Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months ( < 0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms.
Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.
评估从前列腺素类似物（PGA）单药治疗转换为他氟前列素/噻吗洛尔固定复方制剂（Taf/Tim）治疗的疗效和安全性。
纳入接受PGA单药治疗至少3个月的原发性开角型青光眼、正常眼压性青光眼或高眼压症患者。在更换治疗方案后的1、2和3个月对患者进行检查。随后，患者恢复PGA单药治疗。检查的参数包括眼压（IOP）和不良事件。在转换为Taf/Tim治疗后进行问卷调查。
纳入40例平均年龄为66.5±10.3岁的患者；其中39例患者完成了研究方案。转换为Taf/Tim治疗后，眼压从基线时的18.2±2.6 mmHg显著降低至1个月时的14.8±2.5 mmHg、2个月时的15.2±2.8 mmHg和3个月时的14.9±2.5 mmHg（P<0.0）。换回原来的PGA单药治疗后，眼压值恢复到基线水平。Taf/Tim对脉搏率的降低不显著。在血压、结膜充血或角膜不良事件方面未观察到显著差异。问卷调查显示，引入Taf/Tim对症状没有显著影响。
与PGA单药治疗相比，Taf/Tim固定复方制剂治疗可显著降低眼压，且无严重不良事件。
